The new factor Xa inhibitor: Apixaban

Journal of Pharmacology and Pharmacotherapeutics

Volumn 5, Issue 1, 2014, Pages 12-14

  Bhanwra, Sangeeta ^a   Ahluwalia, Kaza ^a  

^a GOVERNMENT MEDICAL COLLEGE AND HOSPITAL   (India)

Author keywords

Apixaban; atrial fibrillation; factor Xa inhibitors; thrombosis

Indexed keywords

APIXABAN;

BLEEDING; CEREBROVASCULAR ACCIDENT; DRUG APPROVAL; DRUG EFFICACY; DRUG INDICATION; DRUG USE; HEART ATRIUM FIBRILLATION; HUMAN; REVIEW; THROMBOSIS; TOTAL HIP PROSTHESIS; TOTAL KNEE REPLACEMENT;

EID: 84892767458     PISSN: 0976500X     EISSN: None     Source Type: Journal    
DOI: 10.4103/0976-500X.124409     Document Type: Review

References (19)

1. Eikelboom JW, Weitz JI. New anticoagulants. Circulation 2010;121:1523-32.
2. Augoustides JG. Breakthroughs in anticoagulation: Advent of the oral direct factor Xa inhibitors. J Cardiothorac Vasc Anesth 2012;26:740-5.
3. Lassen MR, Raskob GE, Gallus A, Pineo G, Chen D, Hornick P, et al. Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2) A randomised double-blind trial. Lancet 2010;375:807-15.
4. Lassen MR, Gallus A, Raskob GE, Pineo G, Chen D, Ramirez LM, et al. Apixaban versus enoxaparin for thromboprophylaxis after hip replacement. N Engl J Med 2010;363:2487-98.
5. Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011;365:981-92.
6. Connolly SJ, Eikelboom J, Joyner C, Diener HC, Hart R, Golitsyn S, et al. Apixaban in patients with atrial fibrillation. N Engl J Med 2011;364:806-17.
7. Buller H, Deitchman D, Prins M, Segers A. Efficacy and safety of the oral direct factor Xa inhibitor apixaban for symptomatic deep vein thrombosis. The Botticelli DVT dose-ranging study. J Thromb Haemost 2008;6:1313-8.
8. Alexander JH, Lopes RD, James S, Kilaru R, He Y, Mohan P, et al. Apixaban with antiplatelet therapy after acute coronary syndrome. N Engl J Med 2011;365:699-708.
9. Yates SW. Apixaban for stroke prevention in atrial fibrillation: A review of the clinical trial evidence. Hosp Pract (1995) 2011;39:7-16.
10. Alexander JH, Becker RC, Bhatt DL, Cools F, Crea F, et al. Apixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: Results of the apixaban for prevention of acute ischemic and safety events trial. Circulation 2009;119:2877-85.
11. Agnelli G, Buller HR, Cohen A, Curto M, Gallus AS, Johnson M, et al. Apixaban for extended treatment of venous thromboembolism. N Engl J Med 2013;368:699-708.
12. Wang L, Zhang D, Raghavan N, Yao M, Ma L, Frost CE, et al. In vitro assessment of metabolic drug-drug interaction potential of apixaban through cytochrome P450 phenotyping, inhibition, and induction studies. Drug Metab Dispos 2010;38:448-58.
13. Nutescu E, Chuatrisorn I, Hellenbart E. Drug and dietary interactions of warfarin and novel oral anticoagulants: An update. J Thromb Thrombolysis 2011;31:326-43.
14. Goldhaber SZ, Leizorovicz A, Kakkar AK, Haas SK, Merli G, Knabb RM, et al. Apixaban versus enoxaparin for thromboprophylaxis in medically ill patients. N Engl J Med 2011;365:2167-77.
15. Greer IA. Thrombosis in pregnancy: Updates in diagnosis and management. Hematology Am Soc Hematol Educ Program 2012;2012:203-7.
16. Cutts BA, Dasgupta D, Hunt BJ. New directions in the diagnosis and treatment of pulmonary embolism in pregnancy. Am J Obstet Gynecol 2013;208:102-8.
17. RxList. The internet drug index [Internet]. California. WebMD; 2008. Available from: http://www.rxlist.com/eliquis-drug.htm [Last updated 2013 Oct 01].
18. Siegal DM, Crowther MA. Acute management of bleeding in patients on novel oral anticoagulants. Eur Heart J 2013;34:489-98b.
19. Perez A, Eraso LH, Merli GJ. Implications of new anticoagulants in primary practice. Int J Clin Pract 2013;67:139-56.